Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
Linde Dekker et al.
BLOOD ADVANCES (2022)
Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab
Kitsada Wudhikarn et al.
BLOOD ADVANCES (2022)
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
Vanessa A. Fabrizio et al.
BLOOD ADVANCES (2022)
Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Yukio Kobayashi et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022)
Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia
Noelle Frey
BLOOD (2022)
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment
Chiara Sartor et al.
HEMATOLOGICAL ONCOLOGY (2022)
Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia
Theodore W. Laetsch et al.
LEUKEMIA (2022)
Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia
Kyaw Hein et al.
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY (2022)
Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States
Bijal D. Shah et al.
ADVANCES IN THERAPY (2022)
Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience
Bhagirathbhai Dholaria et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing
Muna Qayed et al.
CYTOTHERAPY (2022)
MonitoringCAR-Tcell kinetics in clinical trials by multiparameteric flow cytometry: Benefits and challenges
Ghanashyam Sarikonda et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2021)
Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL
Hanna Kirchhoff et al.
BLOOD (2021)
Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Pilar Martinez Sanchez et al.
BLOOD (2021)
Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes
Sobia Aamir et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy
Jing Pan et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)
Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
Erin M. Hall et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22
Hagop M. Kantarjian et al.
CLINICAL CANCER RESEARCH (2021)
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial
Patrick A. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia
Josep-Maria Ribera et al.
BLOOD (2021)
Relapsed ALL: CAR T vs transplant vs novel therapies
Noelle V. Frey
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2021)
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant
Cristina Papayannidis et al.
HEMATOLOGICAL ONCOLOGY (2021)
Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
CANCERS (2021)
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days
Lekha Mikkilineni et al.
BLOOD ADVANCES (2021)
Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
Michael R. Verneris et al.
BLOOD ADVANCES (2021)
Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
G. Doug Myers et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency
Sandheeah Ramdeny et al.
BLOOD ADVANCES (2021)
Hematopathologic Correlates of CAR T-Cell Therapy
J. Gregory Dolan et al.
CLINICS IN LABORATORY MEDICINE (2021)
Low incidence of hepatic veno-occlusive disease (VOD) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin (INO) followed by allogeneic stem cell transplantation (allo-SCT).
Kirk Cahill et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Bijal D. Shah et al.
LANCET (2021)
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
John E. Levine et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Tisagenlecleucel Therapy: Nursing Considerations for the Outpatient Setting
Kathleen Cunningham et al.
SEMINARS IN ONCOLOGY NURSING (2021)
Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies
Ibrahim Aldoss et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
Warren Fingrut et al.
CURRENT ONCOLOGY (2021)
Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
C. Greil et al.
BONE MARROW TRANSPLANTATION (2021)
Bone Marrow Necrosis in a Patient Following Blinatumomab Therapy
Nese Yarali et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2020)
Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?
Prajwal Dhakal et al.
LEUKEMIA & LYMPHOMA (2020)
Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events
Matthias Klinger et al.
CANCER RESEARCH (2020)
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Ibrahim Yakoub-Agha et al.
HAEMATOLOGICA (2020)
The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma
Sahra Ali et al.
ONCOLOGIST (2020)
Safety and efficacy of blinatumomab: a real world data
Arie Apel et al.
ANNALS OF HEMATOLOGY (2020)
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
Noelle Frey et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia
Shuangyou Liu et al.
BLOOD CANCER JOURNAL (2020)
CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
Francesco Lanza et al.
CANCERS (2020)
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
Tania Jain et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)
Outcome of CD20-positive Adult B-cell Acute Lymphoblastic Leukemia and the Impact of Rituximab Therapy
Hanan Alduailej et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin
Talha Badar et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Informative censoring - a neglected cause of bias in oncology trials
Arnoud J. Templeton et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
Joshua A. Hill et al.
BLOOD (2020)
Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome
Nirav N. Shah et al.
BLOOD ADVANCES (2020)
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab
Talha Badar et al.
BLOOD ADVANCES (2020)
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
Tania Jain et al.
BLOOD ADVANCES (2020)
Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases
Miyuki Okura et al.
INTERNAL MEDICINE (2020)
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide
Jonathan A. Webster et al.
BLOOD ADVANCES (2020)
ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Alan S. Wayne et al.
BLOOD (2020)
Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)
Nicola Goekbuget et al.
BLOOD (2020)
Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress
Joanna. Matuszkiewicz-Rowinska et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2020)
Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy
Francesco Paolo Tambaro et al.
CLINICAL CASE REPORTS (2020)
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management
Martina Pennisi et al.
BLOOD ADVANCES (2020)
Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors
Anthony S. Stein et al.
ANNALS OF HEMATOLOGY (2019)
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
Hagop M. Kantarjian et al.
CANCER (2019)
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Mohamed-Reda Benmebarek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
Thomas E. Delea et al.
PHARMACOECONOMICS (2019)
Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials
Montserrat Carrasco-Triguero et al.
BIOANALYSIS (2019)
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
Xinjie Xu et al.
FRONTIERS IN IMMUNOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling
Jennifer E. Hibma et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
Rebecca A. Gardner et al.
BLOOD (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease
Jason Chen et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia
Moshe Yeshurun et al.
BLOOD ADVANCES (2019)
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia
Joseph Wynne et al.
BLOOD ADVANCES (2019)
CAR T Cell Toxicity: Current Management and Future Directions
Lucrecia Yanez et al.
HEMASPHERE (2019)
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
Vinodh Pillai et al.
BLOOD ADVANCES (2019)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Hypogammaglobulinemia due to CAR T-cell therapy
Michael A. Pulsipher
PEDIATRIC BLOOD & CANCER (2018)
Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
Max S. Topp et al.
BLOOD (2018)
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review
Partow Kebriaei et al.
BONE MARROW TRANSPLANTATION (2018)
Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
CANCER (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Phase 2 Clinical Trial
Elias Jabbour et al.
JAMA ONCOLOGY (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
T cell dysfunction in pediatric cancer patients at diagnosis and after chemotherapy can limit chimeric antigen receptor potential
Rajat K. Das et al.
CANCER RESEARCH (2018)
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
Stephanie Vairy et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Karen Thudium Mueller et al.
CLINICAL CANCER RESEARCH (2018)
Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia
Stephan A. Grupp et al.
BLOOD (2018)
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
Mehrdad Hefazi et al.
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY (2018)
No free rides: management of toxicities of novel immunotherapies in ALL, including financial
Tania Jain et al.
BLOOD ADVANCES (2018)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Giovanni Martinelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
Daniel J. DeAngelo et al.
BLOOD ADVANCES (2017)
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
D. Sommermeyer et al.
LEUKEMIA (2016)
Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin
Alison M. Betts et al.
AAPS JOURNAL (2016)
The PI3K pathway in B cell metabolism
Julia Jellusova et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2016)
Blinatumomab provoked fatal heart failure
Behrad Darvishi et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
Sebastien Maury et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
Kum Ja Lee et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Blinatumomab may induce graft versus host leukemia in patients with pre-B ALL relapsing after hematopoietic stem cell transplant
Muhammad Waqas Khan et al.
CLINICAL CASE REPORTS (2016)
G-CSF and GM-CSF in Neutropenia
Hrishikesh M. Mehta et al.
JOURNAL OF IMMUNOLOGY (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes
M. Makatsori et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2014)
Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
G. Zugmaier et al.
BLOOD CANCER JOURNAL (2014)
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T. Teachey et al.
BLOOD (2013)
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
Hagop Kantarjian et al.
CANCER (2013)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma
Michinori Ogura et al.
CANCER SCIENCE (2012)
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2012)
The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells
J. F. de Vries et al.
LEUKEMIA (2012)
Blinatumomab: A historical perspective
Dirk Nagorsen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia
Pier Paolo Piccaluga et al.
LEUKEMIA & LYMPHOMA (2011)
The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates
Elizabeth Fox et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
Deborah A. Thomas et al.
BLOOD (2009)
CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL
Y. Kong et al.
LEUKEMIA (2008)
Management and preparedness for infusion and hypersensitivity reactions
Heinz-Josef Lenz
ONCOLOGIST (2007)
High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication
F. Cabanillas et al.
ANNALS OF ONCOLOGY (2006)
Autologous stem cell transplant in ALL: who should we be transplanting in first remission?
A. R. Mato et al.
BONE MARROW TRANSPLANTATION (2006)
Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
A Löffler et al.
LEUKEMIA (2003)
Share Paper
